Stryker Co. (SYK) Expected to Announce Earnings of $1.83 Per Share

Analysts expect that Stryker Co. (NYSE:SYK) will post earnings of $1.83 per share for the current fiscal quarter, Zacks reports. Eleven analysts have provided estimates for Stryker’s earnings. The lowest EPS estimate is $1.77 and the highest is $1.87. Stryker posted earnings per share of $1.68 during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.9%. The company is scheduled to report its next quarterly earnings report on Thursday, April 25th.

According to Zacks, analysts expect that Stryker will report full-year earnings of $8.12 per share for the current financial year, with EPS estimates ranging from $7.96 to $8.17. For the next fiscal year, analysts forecast that the firm will report earnings of $8.94 per share, with EPS estimates ranging from $8.83 to $9.07. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Stryker.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.03. The firm had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%.

Several research analysts have weighed in on the company. Royal Bank of Canada upped their target price on Stryker from $184.00 to $204.00 and gave the stock an “outperform” rating in a research report on Monday. Barclays set a $203.00 target price on Stryker and gave the stock a “buy” rating in a research report on Friday, March 8th. Morgan Stanley upped their target price on Stryker from $200.00 to $218.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $205.00 target price on shares of Stryker in a research report on Friday, March 1st. Finally, Zacks Investment Research raised Stryker from a “hold” rating to a “buy” rating and set a $199.00 target price on the stock in a research report on Monday, February 4th. Seven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $188.35.

In other news, VP Katherine Ann Owen sold 29,247 shares of Stryker stock in a transaction on Friday, March 8th. The shares were sold at an average price of $185.62, for a total transaction of $5,428,828.14. Following the completion of the sale, the vice president now directly owns 11,131 shares of the company’s stock, valued at approximately $2,066,136.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 180 shares of Stryker stock in a transaction on Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,811 shares of company stock valued at $13,409,320. 7.30% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the stock. Landsberg Bennett & Dubbaneh LLC purchased a new position in shares of Stryker in the fourth quarter valued at about $1,926,000. Cerity Partners LLC increased its position in shares of Stryker by 8.9% during the fourth quarter. Cerity Partners LLC now owns 10,644 shares of the medical technology company’s stock valued at $1,668,000 after buying an additional 874 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Stryker during the third quarter valued at about $26,368,000. CWM LLC increased its position in shares of Stryker by 309.8% during the fourth quarter. CWM LLC now owns 23,792 shares of the medical technology company’s stock valued at $3,729,000 after buying an additional 17,986 shares during the period. Finally, Banco Santander S.A. purchased a new position in shares of Stryker during the third quarter valued at about $3,169,000. Institutional investors own 75.46% of the company’s stock.

NYSE:SYK traded up $0.69 during trading hours on Friday, hitting $194.04. 1,734,335 shares of the company’s stock traded hands, compared to its average volume of 1,481,983. The firm has a market capitalization of $71.49 billion, a price-to-earnings ratio of 26.54, a PEG ratio of 2.34 and a beta of 0.88. Stryker has a twelve month low of $144.75 and a twelve month high of $194.80. The company has a current ratio of 2.02, a quick ratio of 1.41 and a debt-to-equity ratio of 0.72.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a yield of 1.07%. Stryker’s payout ratio is 28.45%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.